Dynavax Technologies (DVAX)

• Market cap: $1.2B
• 1 day: -1.35%
• 5 days: -1.44%
• 1 month: 3.32%
• 3 months: -6.56%
• 6 months: -12.68%
• Year to date: -20.47%
• 1 year: -13.42%
• 5 years: 172.87%
• 10 years: -58.17%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Employees: 405